The pharmaceutical industry, as well as academic basic science, depend on robust data and scientific rigor for decision making, patent strength and time-to-market for novel patient treatment options. Recent publications challenge the quality of research data, which may impact translatability and predictability of preclinical models. There is a need for simple, sustainable solutions that improve data quality.
The objectives of the IMI project EQIPD are to:
- enable the development of quality criteria for future preclinical tests
- develop consensus quality management system for the non-regulated R&D in industry and academia to enhance the quality of decisions made based on experimental, exploratory or hypothesis-testing data
- develop an online educational platform on scientific quality principles which catalyses the cultural change needed to enhance quality value and sustainability of the findings of preclinical research.
J Vollert, E Schenker, M Macleod, A Bespalov, H Wuerbel, MC Michel, U Dirnagl, H Potschka, KE Wever, T Steckler, B Altevogt, ASC Rice on behalf of the EQIPD WP3 study group. Protocol for a systematic review of guidelines for rigour in the design, conduct and analysis of biomedical experiments involving laboratory animals. BMJ Open Science 2(1). E-pub